KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Interest & Investment Income (2016 - 2025)

Jazz Pharmaceuticals has reported Interest & Investment Income over the past 16 years, most recently at -$45.4 million for Q4 2025.

  • Quarterly Interest & Investment Income rose 11.41% to -$45.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$192.6 million through Dec 2025, up 19.11% year-over-year, with the annual reading at -$195.1 million for FY2025, 18.08% up from the prior year.
  • Interest & Investment Income was -$45.4 million for Q4 2025 at Jazz Pharmaceuticals, up from -$48.6 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at -$27.4 million in Q1 2021 and troughed at -$93.4 million in Q3 2021.
  • The 5-year median for Interest & Investment Income is -$69.4 million (2021), against an average of -$65.0 million.
  • Biggest five-year swings in Interest & Investment Income: tumbled 240.43% in 2021 and later rose 27.11% in 2024.
  • Tracing JAZZ's Interest & Investment Income over 5 years: stood at -$88.6 million in 2021, then rose by 16.34% to -$74.1 million in 2022, then increased by 5.13% to -$70.3 million in 2023, then rose by 27.11% to -$51.3 million in 2024, then grew by 11.41% to -$45.4 million in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at -$45.4 million, -$48.6 million, and -$47.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.